| 31.28 -0.36 (-1.14%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 38.69 | 1-year : | 45.19 |
| Resists | First : | 33.13 | Second : | 38.69 |
| Pivot price | 30.11 |
|||
| Supports | First : | 29.32 |
Second : | 26.97 |
| MAs | MA(5) : | 31.23 |
MA(20) : | 29.54 |
| MA(100) : | 24.01 |
MA(250) : | 24.54 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 70 |
D(3) : | 71.5 |
| RSI | RSI(14): 62.4 |
|||
| 52-week | High : | 33.13 | Low : | 17.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BLFS ] has closed below upper band by 25.1%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.73 - 31.89 | 31.89 - 32.02 |
| Low: | 30.57 - 30.78 | 30.78 - 30.95 |
| Close: | 30.98 - 31.3 | 31.3 - 31.57 |
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.
Sat, 01 Aug 2026
BioLife Solutions, Inc. Revenue Breakdown – NASDAQ:BLFS - tradingview.com
Thu, 30 Jul 2026
BioLife Solutions (NASDAQ:BLFS) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Wed, 29 Jul 2026
BioLife Solutions, Inc. (BLFS) Stock Forecasts - Yahoo Finance
Wed, 29 Jul 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LXP, BLFS, PSNL, and FNWD - Morningstar
Wed, 29 Jul 2026
BioLife Solutions Inc (BLFS) Institutional Confidence - TradingKey
Tue, 28 Jul 2026
BioLife Solutions, Inc. (BLFS) Investor Outlook: Navigating Growth with a 4.9% Upside Potential - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 49 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 103.9 (%) |
| Shares Short | 2,860 (K) |
| Shares Short P.Month | 3,630 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.61 |
| Profit Margin | -3 % |
| Operating Margin | 0.1 % |
| Return on Assets (ttm) | -0.1 % |
| Return on Equity (ttm) | -3.1 % |
| Qtrly Rev. Growth | 24.7 % |
| Gross Profit (p.s.) | 1.32 |
| Sales Per Share | 2.08 |
| EBITDA (p.s.) | 0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 18 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -130.34 |
| PEG Ratio | 15 |
| Price to Book value | 4.1 |
| Price to Sales | 15.03 |
| Price to Cash Flow | 85.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|